Buscar en RiuNet

Listar

Mostrando ítems 1-2 de 2

Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)

Iranzo, Vega; Sirera Pérez, Rafael; Carrato, Alfredo; Cabrera, Andrea; Jantus, Eloísa; Guijarro, Ricardo; Sanmartín, Elena; Blasco, Ana; Gil, Mireia; Gómez Aldaraví, Lorenzo; González Larriba, José Luis; Massuti, Bertomeu; Velasco, Amalia; Provencio, Mariano; Rosell, Rafael; Camps, Carlos (Springer, 2011-06)

[EN] Background: In advanced-stage (IIIB or IV) non-small-cell lung cancer (NSCLC), combination chemotherapy has demonstrated response rates of 20% and a 1-year survival rate of 30%. We conducted a multicentre, open-label, ...
The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients

Camps, Carlos; Jantus Lewintre, Eloisa; Cabrera, Andrea; Blasco, Ana; Sanmartin, Elena; Gallach, Sandra; Caballero, Cristina; del Pozo, Nieves; Rosell, Rafael; Guijarro, Ricardo; Sirera Pérez, Rafael (Elsevier, 2011-06)

Qualitative analysis of circulating DNA in the blood is a promising non-invasive diagnostic and prognostic tool. Our aim was to study the association between the presence of KRAS mutations at codon 12 and several clinical ...

Mostrando ítems 1-2 de 2